Introduction
Coronary artery disease is the leading cause of ischemic cardiomyopathy. Impairment in left ventricular dysfunction can result from a spectrum of myocardial injury, including ischemia and myocardial necrosis, causing progressive tissue remodeling.[1] Approximately half of the patients with coronary artery disease can have dysfunctional hibernating myocardium that is potentially reversible with restoration of blood flow. Earlier identification of these areas can have profound prognostic implications.[2] Most noninvasive imaging techniques can assess wall motion abnormalities and function, including echocardiography, coronary computed tomography angiography (CCTA), magnetic resonance imaging (MRI), and nuclear studies. However, each technique has distinct characteristics that can help decide which study should be performed based on the clinical indication.An echocardiogram is often the initial study of choice for assessing cardiac function in critically ill or unstable patients, as it can be conveniently performed at the bedside and is not associated with radiation. Thus, it can be safely used in both pregnant and pediatric patients. CCTA is the best noninvasive technique to evaluate anomalous vessels, luminal irregularities, and stenosis of the coronary vasculature.[3] Cardiac magnetic resonance (CMR) and nuclear studies can better characterize abnormalities within myocardial tissue, such as scar formation or infiltrative processes. Additionally, myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT) and positron emission tomography (PET) provides information regarding tissue viability and perfusion defects and can further guide treatment. Invasive coronary angiography serves as a diagnostic and therapeutic assessment tool to restore vascularization and potentially improve ventricular dysfunction.
Procedures
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Procedures
Compromise of myocardial blood flow results in ischemia, which activates inflammatory pathways that lead to a spectrum of myocardial injury. This injury can be reversible in myocardial stunning or hibernation, but chronic or severe ischemia leads to apoptosis and necrosis at the cellular level, resulting in irreversible fibrosis. Based on their severity, these changes manifest as regional wall motion abnormalities on echocardiography, CCTA, or MRI, and/or perfusion defects on myocardial perfusion imaging.
Infarct-avid imaging has an increasing role in the noninvasive evaluation of coronary artery disease. Unlike echocardiography or CCTA, cardiac SPECT imaging uses the redistribution of radioactive tracer uptake in the myocardium, both at rest and with exercise or vasodilator stress, to identify areas of potentially reversible ischemia.[4][5] The most commonly used radiotracers are technetium-labeled radiotracers, which include Tc-99m sestamibi, Tc-99m pyrophosphate, Tc-99m tetrofosmin, and thallium-201.[6] Technetium-labeled radiotracers rely on passive diffusion across viable sarcolemmal and mitochondrial membranes, whereas thallium-201 requires active transport via Na/K ATPase within sarcomeric membranes for tracer uptake.[7][8]
Damaged myocardial cells with compromised permeability or hypoperfusion from stenotic lesions result in decreased radiotracer uptake, which may indicate obstructive coronary artery disease. Findings of new wall motion abnormalities, ventricular dilatation, and lack of improvement in poststress ejection fraction on SPECT imaging may have poor prognostic value. An advantage of technetium-based radiotracers over thallium is lower radiation exposure and improved soft-tissue attenuation, resulting in better image quality, which can be particularly helpful in female patients.
Positron emission tomography (PET) imaging assesses the uptake of F-fluorodeoxyglucose (F-FDG), a glucose analog. Under ischemic conditions, myocytes switch from fatty acid-based to glucose-based metabolism; new FDG-positive areas suggest regional ischemia. Comparative studies have found PET imaging to have slightly better sensitivity (92%) than SPECT imaging (85%), with better spatial resolution and lower radiation exposure. Despite these small differences, a randomized trial suggested similar results for clinical decision-making using SPECT versus PET-based techniques.[9]
Cardiac magnetic resonance (CMR) is another noninvasive technique that can detect areas of ischemia and infarction, but is commonly used to evaluate inflammatory and infiltrative processes affecting the myocardium and pericardium. Furthermore, concurrent cardiac gating allows the measurement of right and left ventricular function. A cardinal feature of CMR is the late gadolinium enhancement (LGE) percentage of wall thickness, which has greater than 90% specificity in predicting myocardial viability.[10] LGE detects the increase in the extracellular space following myocardial necrosis due to ischemia. An involved region of less than 25% indicates a higher likelihood of recovery following revascularization, whereas an involved region greater than 50% indicates a lower likelihood.[11]
Both invasive coronary angiography with cardiac catheterization and coronary CT angiography (CCTA) evaluate anatomic defects of the coronary vessels, such as anomalous coronaries or coronary atherosclerosis. Both techniques require iodinated contrast injection to characterize the lumen of coronary vessels. Although coronary CTA can provide detailed plaque characterization and identify culprit lesions, coronary angiography remains the gold-standard technique for both diagnosis and therapeutic intervention.[3]
Indications
Noninvasive infarct-avid myocardial perfusion imaging can be particularly useful in evaluating acute myocardial infarction and coronary artery disease when conventional diagnostic methods are limited. A late presentation of suspected acute myocardial infarction after approximately 7 days in the context of equivocal clinical history, absent or uninterpretable diagnostic electrocardiogram (EKG) findings, and negative cardiac biomarkers can be challenging to diagnose. Tissue characterization, including new areas with reversible ischemia, old infarcts, or viable myocardium, can be identified using myocardial perfusion imaging.
Exercise stress testing is the most commonly utilized means of risk stratification in patients with low to intermediate pretest probability of coronary artery disease. However, in the presence of baseline EKG abnormalities such as a left bundle branch block, left ventricular hypertrophy, preexcitation, paced rhythm, or baseline ST-segment depression, results of exercise stress testing may be uninterpretable. An allergic reaction to iodine/ iodinated contrast is a contraindication for CCTA, while a morbidly obese patient may have poor windows for visualization with echocardiography. In such scenarios, including pregnancy, CMR can be a useful diagnostic modality in evaluating coronary artery disease. In patients who are suspected of having new ischemia after recently having undergone coronary artery bypass grafting or other major surgical procedures, SPECT and PET can also help identify areas of new periprocedural infarcts.
Coronary CTA can be used to evaluate a patient with an intermediate pretest probability of coronary artery disease and to assess coronary artery defects, such as anomalous coronaries. Coronary angiography and catheterization offer both diagnostic and therapeutic interventions. Techniques such as fractional flow reserve (FFR), used during coronary catheterization, evaluate blood flow under conditions of maximal hyperemia to help identify clinically significant stenosis and potentially guide revascularization strategies, including percutaneous coronary intervention, bypass grafting, or medical management.[3]
Normal and Critical Findings
Abnormal imaging findings vary depending on the imaging study utilized to evaluate coronary artery disease. For example, regional wall motion abnormalities on echocardiography, CCTA, or MRI, and/or perfusion defects on myocardial perfusion imaging indicate ischemia or infarction. Furthermore, a global reduction in wall motion, ventricular dilatation, and lack of improvement in post-stress ejection fraction on SPECT imaging may portend a poor prognosis.
Abnormal enhancement on cardiac magnetic resonance helps identify inflammatory and infiltrative processes affecting the myocardium and pericardium, as well as ischemic or infarcted regions. CT angiography can detect anomalous vessels and luminal stenosis of the coronary vasculature. Furthermore, interventional techniques such as measuring fractional flow reserve can further characterize areas of critical stenosis that may benefit from therapeutic intervention.[3]
Interfering Factors
An important consideration in myocardial perfusion imaging is the timing of radiotracer administration relative to the presumed onset of infarction, as maximum deposition in infarcted areas occurs approximately 48 to 72 hours after the ischemic event, with subsequent clearance. Hence, studies performed within 24 hours or past 7 days have higher rates of false-negative results. Obtaining serial scans at 48 to 72-hour intervals can increase diagnostic yield.[6]
False-negative results may arise when a heavy burden of diffuse coronary artery disease with poor collateral circulation causes "balanced ischemia" from global hypoperfusion. There may also be a significant delay in radiotracer penetrance within myocardial tissue, so repeating a study about 4 to 5 days later may help improve diagnostic yield. Decreased myocardial mass in the inferior and posterior walls, compared with the anterior and lateral walls, or in smaller infarction territories, may decrease sensitivity. However, serial scans can significantly improve the detection of small infarcts.[12]
The presence of intracardiac or valvular calcifications, ventricular aneurysm, infiltrative diseases such as amyloidosis, anthracycline toxicity, radiation therapy, and scarring from prior myocardial infarction can cause false-positive results when technetium pyrophosphate tracer is used in SPECT imaging.[13] Due to the short half-life of PET radiotracers, cardiac PET requires concurrent administration of vasodilators. Other limitations include limited anatomic detail of coronary calcification due to attenuation correction. Many studies have shown high rates of false-negative results in patients with insulin resistance and low cardiac output.
Potential contraindications to cardiac MRI include metal devices or implants, such as cardiac implanted electronic devices, wires, clips, and foreign bodies. A comprehensive patient screening is mandatory to assess potential risks before the MRI. CMR requires longer image acquisition times in a still position, which may be difficult for certain patients to tolerate.[10] Heavy coronary calcifications on CTA may cause artifacts that may impact the interpretation of results, and smaller distal vessels may be poorly visualized.
Complications
Complications are typically associated with invasive techniques and the use of contrast material. Although rarely seen with gadolinium, the theoretical risk of nephrogenic systemic fibrosis remains a concern, especially in patients with poor kidney function. Both CCTA and coronary angiography with catheterization must be done with caution in patients with severely reduced renal function, given the use of contrast, and both imaging techniques involve radiation exposure. Despite cardiac catheterization being the gold standard imaging modality in the evaluation of coronary artery disease, risks include bleeding, infection, retroperitoneal hemorrhage, dysrhythmias, pseudoaneurysms, coronary artery dissection, tamponade, pneumothorax, and death.[14]
Patient Safety and Education
Depending on the imaging study a patient is undergoing, patients are encouraged to follow specific instructions to optimize results. Patients are usually required to avoid oral intake after midnight before a myocardial perfusion imaging study to minimize the risk of increased gastric metabolic activity interfering with the evaluation of the inferior wall. Additionally, caffeine, other sympathomimetic medications, nitroglycerin, or beta-blockers should be held to optimize evaluation for coronary artery disease. Jewelry and other metal objects should not be worn to avoid potential imaging artifacts. Patients are encouraged to wear comfortable clothing and shoes for exercise stress testing.[15]
Clinical Significance
Noninvasive imaging modalities such as SPECT, PET, and CMR are increasingly important in assessing tissue characterization, cardiac function, and areas of infarction to further guide patient management and therapeutic strategy. In addition to functional and anatomic information, the pattern and extent of radiotracer uptake, as well as the duration of a positive study, provide prognostic information. Using this information allows the clinician to develop a therapeutic approach that optimizes medical therapy or revascularization via invasive techniques to improve cardiac dysfunction.
The spectrum of ischemic heart disease can encompass temporary impairment in cardiac function that’s often reversible with restoration of blood flow to infarcted areas from myocyte necrosis, rendering them irreversible. As rates of obesity increase in the United States, the rates of coronary artery disease are also expected to increase concurrently. As discussed above, various imaging modalities are key components in evaluating and managing coronary artery disease. It is important to consider the study indication, costs, contraindications, and procedural risks, tailored to each patient's unique characteristics, to determine the best study to perform. Consultation should be considered to ensure that appropriate studies are ordered to obtain the intended information.
References
American College of Cardiology Foundation Task Force on Expert Consensus Documents, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Journal of the American College of Cardiology. 2010 Jun 8:55(23):2614-62. doi: 10.1016/j.jacc.2009.11.011. Epub [PubMed PMID: 20513610]
Level 3 (low-level) evidencevan Heertum RL. Infarct avid imaging study in the radionuclide diagnosis of acute myocardial infarction. Bulletin of the New York Academy of Medicine. 1981 Nov:57(9):747-54 [PubMed PMID: 6948596]
Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. The New England journal of medicine. 1996 Jun 27:334(26):1703-8 [PubMed PMID: 8637515]
Bonow RO. Identification of viable myocardium. Circulation. 1996 Dec 1:94(11):2674-80 [PubMed PMID: 8941085]
Strauss HW, Narula J, Blankenberg FG. Radioimaging to identify myocardial cell death and probably injury. Lancet (London, England). 2000 Jul 15:356(9225):180-1 [PubMed PMID: 10963191]
Level 3 (low-level) evidenceKronenberg MW, Wooten NE, Friesinger GC, Page DL, Higgins SB, Collins JC, O'Connor JL, Price RR, Brill AB. Scintigraphic characteristics of experimental myocardial infarct extension. Circulation. 1979 Nov:60(5):1130-40 [PubMed PMID: 487546]
Level 3 (low-level) evidencePiwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation. 1990 Nov:82(5):1826-38 [PubMed PMID: 2225379]
Level 3 (low-level) evidenceSeitun S, De Lorenzi C, Cademartiri F, Buscaglia A, Travaglio N, Balbi M, Bezante GP. CT Myocardial Perfusion Imaging: A New Frontier in Cardiac Imaging. BioMed research international. 2018:2018():7295460. doi: 10.1155/2018/7295460. Epub 2018 Oct 14 [PubMed PMID: 30406139]
Siebelink HM, Blanksma PK, Crijns HJ, Bax JJ, van Boven AJ, Kingma T, Piers DA, Pruim J, Jager PL, Vaalburg W, van der Wall EE. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. Journal of the American College of Cardiology. 2001 Jan:37(1):81-8 [PubMed PMID: 11153777]
Level 1 (high-level) evidenceSiddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends in cardiovascular medicine. 2018 Jan:28(1):10-21. doi: 10.1016/j.tcm.2017.07.004. Epub 2017 Jul 13 [PubMed PMID: 28739313]
Level 2 (mid-level) evidenceLaspas F, Pipikos T, Karatzis E, Georgakopoulos N, Prassopoulos V, Andreou J, Moulopoulos LA, Chatziioannou A, Danias PG. Cardiac Magnetic Resonance Versus Single-Photon Emission Computed Tomography for Detecting Coronary Artery Disease and Myocardial Ischemia: Comparison with Coronary Angiography. Diagnostics (Basel, Switzerland). 2020 Mar 29:10(4):. doi: 10.3390/diagnostics10040190. Epub 2020 Mar 29 [PubMed PMID: 32235380]
Kuşlu D, Öztürk E. A Comparison of Iterative Reconstruction and Prone Imaging in Reducing the Inferior Wall Attenuation in Tc-99m Sestamibi Myocardial Perfusion SPECT. Molecular imaging and radionuclide therapy. 2017 Oct 3:26(3):110-115. doi: 10.4274/mirt.83007. Epub [PubMed PMID: 28976333]
Wald RW, Sternberg L, Huckell VF, Staniloff HM, Feiglin DH, Morch JE. Technetium-99m stannous pyrophosphate scintigraphy in patients with calcification within the cardiac silhouette. British heart journal. 1978 May:40(5):547-51 [PubMed PMID: 207292]
Johnson LW, Lozner EC, Johnson S, Krone R, Pichard AD, Vetrovec GW, Noto TJ. Coronary arteriography 1984-1987: a report of the Registry of the Society for Cardiac Angiography and Interventions. I. Results and complications. Catheterization and cardiovascular diagnosis. 1989 May:17(1):5-10 [PubMed PMID: 2720767]
Fathala A. Myocardial perfusion scintigraphy: techniques, interpretation, indications and reporting. Annals of Saudi medicine. 2011 Nov-Dec:31(6):625-34. doi: 10.4103/0256-4947.87101. Epub [PubMed PMID: 22048510]